Akebia Therapeutics (AKBA) Misses Q3 EPS by 3c

Akebia Therapeutics (NASDAQ: AKBA) reported Q3 EPS of ($0.46), $0.03 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $92 million versus the consensus estimate of $99.38 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• AI and memory not a classic bubble, but future returns uncertain - strategist
• Darden Restaurants (DRI) Reports In-Line Q1 EPS, Misses on Revenue; Offers FY27 EPS Guidance
• BlackBerry (BB) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance